Description

The global prostate cancer drug market in terms of revenue is set to grow by US$ 11 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 10.5% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for prostate cancer drug. The global prostate cancer drug market is segmented on the basis of type. By type, it is categorized into Abiraterone acetate, Enzalutamide, Goserelin, and Leuprorelin.

The report has profiled some of the key players of the market such as Pfizer Inc., Beijing Biote Pharmaceutical Co. Ltd., Johnson & Johnson International Inc., Livzon Pharmaceutical Group Inc., Takeda Pharmaceutical Co. Ltd.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the prostate cancer drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Type: Abiraterone acetate, Enzalutamide, Goserelin, and Leuprorelin
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the global prostate cancer drug market
Pinpoint growth sectors and trends for investment
Understand what the future of the global prostate cancer drug market looks like
Identify the competitive landscape and window of opportunity

Table of Contents

1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Prostate Cancer Drug Market by Type
4.1 Abiraterone Acetate
4.2 Enzalutamide
4.3 Goserelin
4.4 Leuprorelin
5. Company Profiles
5.1 Pfizer, Inc.
5.2 Beijing Biote Pharmaceutical Co., Ltd.
5.3 Johnson & Johnson International, Inc.
5.4 Livzon Pharmaceutical Group Inc.
5.5 Takeda Pharmaceutical Co. Ltd.
6. Appendix
6.1 About StrategyHelix
6.2 Disclaimer